Bioreactance is a reliable method for estimating cardiac output at rest and during exercise.
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1: The addition of "All authors read and approved the final manuscript" at the end of the 'Authors' contributions' section is fine, the authors are happy with this addition. [1] should be changed to 3: Reference [13] volume is 37 and page numbers should be changed to 3092-7 4: Thankyou for highlighting the affiliations. A few changes need to be made. which include: Introduction 1 Monitoring of cardiac output (CO) has wide clinical application in anesthesiology, 2 emergency care and cardiology. It can improve outcomes, establish diagnosis, guide therapy 3 and help risk stratification in different clinical groups 1 . Measurement of cardiac output is 4 essential in critically ill, injured and unstable patients as it provides an indication of systemic 5 oxygen delivery and global tissue perfusion 2 . Cardiac output monitoring during surgery is 6 associated with reduced length of hospital stay and postoperative complications 3-5 . 7 Measurement of cardiac output under pharmacological and physiological stimulations defines 8 overall function and performance of the heart, predicts prognosis and survival in heart failure 9 can help explain the mechanisms of exercise intolerance, and improves risk stratification [6] [7] [8] [9] [10] . 10 11 Thermodilution and direct Fick 11-13 remain the "gold standard" and reference methods for 12 assessing CO. Whilst "gold standard" these methods have inherent limitations as they are 13 invasive, costly, require specialist skills and associated with noteworthy risks and 14 complications such as catheter-related infections, arrhythmias and bleeding 14 15 . The 15 risk:benefit ratio of these assessment methods has also been brought into question 14 . These 16 limitations preclude the use of invasive cardiac output monitoring in large number of patients 17 limiting the application of this useful diagnostic and prognostic marker. 18 19 Over the previous decades several minimally invasive and non-invasive methods for 20 assessing cardiac output have been developed including; trans-esophageal Doppler, 21 transpulmonary thermodilution, pulse contour and pulse power analysis, and non-invasive 22 techniques such as CO2 and inert gas rebreathing, transthoracic Doppler, thoracic 23 bioimpedance cardiography, and electrical velocimetry (modified bioimpedance) 2 16-18 .
2: Reference
Unfortunately whilst these methods are safe they are associated with certain limitations 1 precluding their accuracy and reliability 13 19 . 2 3 Bioreactance, a novel method for continuous non-invasive cardiac output monitoring, has 4 received increased attention in clinical and research practice in the recent years. The 5 bioreactance method estimates CO by analysing the frequency of relative phase shift of 6 electronic current across the thorax 20 21 . In contrast to impedance cardiography which is based 7 on the analysis of transthoracic voltage amplitude changes in response to high frequency 8 current, the bioreactance analyses the frequency spectra variations of the delivered oscillating 9 current 20 . This approach is supposed to result in the improved precision of the bioreactance 10 system as demonstrated by a 100 fold larger signal-to-noise ratio than that of bioimpedance 11 and thus make it less susceptible to interference from adipose tissue, electrode placement and 12 excessive movement 20 22 . 13
14
The ability of bioreactance to monitor rapid changes in blood flow has recently been 15 confirmed by Marik, et al. 23 . The authors compared carotid Doppler against bioreactance in 16 patients with unstable cardiac conditions during passive leg raising. A strong correlation was 17 reported in blood flow between the two methods in critically ill patients, with an accelerated 18 response to these volume changes reported by bioreactance. Bioreactance cardiac output 19 monitoring has been used in intensive care unit, during and following cardiac surgery, 20 patients with chronic obstructive pulmonary disease and healthy individuals 19 20 22-25 . Other 21 studies demonstrated that bioreactance measurements of cardiac output at rest and during 22 exertion can identify cardiovascular function abnormalities, indexing disease severity, help 23 prognosis and risk stratification, and track responses to treatment in clinical practice 26 27 .
When assessing cardiac output at rest or during physiological challenge, it is essential that 1 method demonstrates acceptable level of reliability i.e. test-retest reliability which refers to 2 the reproducibility of values of a variable when measured the same subjects twice. This is 3 important because even small changes in cardiac output and stroke volume may have 4 significant clinical implications when evaluating the effect of pharmacological and non-5 pharmacological interventions and risk stratification. Based on available literature, it appears 6 that test-retest reliability of bioreactance, as a novel and potent method for non-invasive 7 continuous cardiac output monitoring has not been evaluated. Based on higher signal-to-noise 8 ratio and improved performance 19 20 we hypothesize that bioreactance method demonstrates 9 acceptable test-retest reliability for evaluating cardiac output at rest and during physiological 10 stimulation such as graded exercise testing. Additionally, we evaluated association between 11 cardiac output and oxygen consumption at peak exercise. Twenty two healthy individuals (10 males and 12 females) mean age 21 22 participated in the study. All participants were non-smokers and free from any cardiac and 23 respiratory disorders. All participants attended the exercise laboratory on 2 separate days, day 24 visits consisting of an incremental exercise cycle ergometer protocol at individual pre-1 determined workloads based on participants power output at ̇O 2max (Wmax). Participants 2 were required to abstain from eating for a minimum of 2 hours prior to the commencement of 3 each test and from vigorous exercise 24 hours prior to the test. Participants were also 4 instructed not to consume alcohol and caffeine containing foods and beverages on test days. 5 6 Participants completed a maximal progressive exercise test on an electro-magnetically braked 7 recumbent cycle ergometer (Corival, Lode, Groningen, Netherlands). All participants began 8 cycling against a resistance of 40 W, this increased continually throughout the test at a ramp 9 rate of 15 W min -1 . Cessation of the assessment occurred when participants reached volitional 10 exhaustion or were unable to maintain a cadence of 60-70 revolutions per minute. It was 11 considered that a maximal effort was achieved if participants met any of two of the following 12 criteria: i) a change in ̇O 2 < 2 ml kg min -1 across two stages of the incremental test; ii) a 13 respiratory exchange ratio of 1.15 or greater, or iii) ≥ 90% age predicted maximum heart rate 14 (220-age) 28 . Expired gases were measured via online metabolic gas exchange system (Cortex 15 metalyser 3B, Leipzig, Germany) and heart rate was measured via short range telemetry 16 (Polar RS400, Finland). Peak oxygen consumption was defined as the average oxygen uptake 17 during the last minute of exercise, expressed as millilitres per kilogram of body weight per 18 minute and litres per minute. The Wmax was defined as the power output expressed in W at 19 the point at which participants reached their individual ̇O 2max. 20 21 Exercise protocol was performed twice on study day 2 with ≥ 3 h interval between trials 1 22 and 2. Participants were required to complete five 3 min stages (equating to 15 min of cycling) 23 at intensities relative to 20, 40, 60, 80 and 90% Wmax. Cardiac and hemodynamic responses 24 including cardiac output, cardiac index, stroke volume and stroke volume index, and heart 25 rate were recorded at rest and throughout the incremental exercise protocol using a non-1 invasive bioreactance system (NICOM ® , Cheetah Medical, Delaware, USA). Simultaneously, 2 respiratory and gas exchange measurements were recorded (Cortex metalyser 3B, Leipzig, 3 Germany). 4 5
The bioreactance system comprises of a radio frequency generator that creates a high 6 frequency current that is introduced across the thoracic cavity. The NICOM ® has been 7 described previously 19 20 25 . It analyses the relative phase shift of electronic current across the 8 thorax. In brief the four dual surface electrodes are used to establish electrical contact with 9 the body. The skin was prepared by shaving where required and using adhesive paper to 10 ensure an optimal signal from the electrodes. Two electrodes were placed over the trapezius 11 muscle on either side of the upper torso and two on the lower posterior torso lateral to the 12 margin of the latissimus dorsi musculature. The right and left sensors of the devise generate 13 independent signals which are subsequently integrated to generate the final signal analysed. 14 The blood that is present in the thoracic cavity absorbs electrons, which results in a delay in 15 the signal, which is proportional to the volume of blood flow. This is called a phase shift and 16 is recorded and the figure is translated to the flow of the blood. The signal that is detected by 17 the electrodes is then processed separately and averaged after digital processing at 30 or 60 s 18 intervals. The signal processing unit of the NICOM ® determines the relative phase shift (∆φ) 19 between the input signals relative to the output signal. The ∆φ is in response to any changes 20 in blood flow that pass through the aorta. The CO is then derived by CO = (C x VET x ∆φ 21 dtmax) x HR, where C is the constant of proportionality and VET is ventricular ejection 22 fraction time 19 . The value of C has been previously validated to account for patient age, 23 gender, height and weight 22 . CO can then be calculated from stroke volume and HR. 24
Statistical methods
1 Statistical analyses were performed using PASW statistical analysis software (Version 19, 2 IBM, USA). Data are presented as mean (standard deviation). The alpha level of 0.05 was set 3 prior to data analysis and normality of distribution was assessed using a Smirnov test. Relative reliability was determined using intra-class correlation coefficients 5 (ICC), calculated using the two-way random method previously described by Weir 29 . 6
Absolute reliability was determined using standard error of measurement (SEM) with 95% 7 confidence intervals (95%CI), which were calculated independently of intra-class correlation 8 coefficients. Systemic bias in the repeatability between trials was assessed using paired 9 sample t-tests. The relationship between cardiac output and oxygen consumption was 10 assessed with Pearson's coefficient of correlation. Data analyses were performed on both 11 combined resting and exercise data and data from each individual stage of the incremental 12 exercise protocol for CO, cardiac index (CI), stoke volume (SV), stroke volume index (SVI), 13 heart rate (HR) minute ventilation (VE) and oxygen consumption (̇O2). 14
15
Results
16
Physical characteristics of study participants are: age 26.3 (4.2) years, height 171.5 (8) cm, 17 body mass 67.4 (7.9) kg, and peak oxygen consumption 41.5 (8.7) ml kg min -1 . Data 18 pertaining to the systemic bias between trials for all assessed cardiac and respiratory variables 19 are presented in Table 1 . There was a non-significant (< 5%) difference between trials 1 and 20 Cardiac output was similar between the trials 1 and 2 at rest (0.7 (10.3) %) and all stages of 7 the incremental exercise protocol (Figure 1) . At low exercise intensity i.e. 20-40% of Wmax 8 the differences in cardiac output between trials 1 and 2 were 4 and 1%, respectively. At 9 moderate (i.e. 60% of Wmax) and high (80 and 90% of Wmax) exercise intensity the 10 difference was only between 1 and 2% (Figure 1) . 11
12 Table 3 about here  13   14 Non-significant differences between the trial 1 and 2 were reported for stroke volume at all 15 stages of the protocol, with mean difference ranging from 1% (at 80% of Wmax) to 7% (at 20% 16 of Wmax, Figure 2 ). When resting and exercise data points are considered together (n=132), 17 the mean difference between trial 1 and 2 was only 2%. 18
19 Figure 1 about here 20 21 Participants mean cardiac index and stroke volume index were not significantly different 22 between the trials when data analyses included combined resting and exercise data (Table 1) . 23
Furthermore, neither mean cardiac index nor stroke volume index was significantly different 24 between trials at rest or at any exercise stage. As detailed in Table 1 heart rate, peak oxygen consumption, and mean ventilation were 4 similar between trials. Relative and absolute reliability statistics presented in Tables 2 and 3  5 demonstrate good reliability. In addition, no significant differences between the trials were 6 found in heart rate, peak oxygen consumption, and mean ventilation at rest or at any of the 7 exercise intensities (p > 0.05). 8 9 Data demonstrate a strong relationship between cardiac output and oxygen consumption at 10 peak exercise for both trials (Trial 1; r = 0.64, p = 0.001, Trial 2; r = 0.66, p < 0.001). 11 12
Discussion
13
The primary finding of this study is that bioreactance demonstrates acceptable test-retest 14 reliability for estimating cardiac output and stroke volume at rest and during physiological 15 stress induced by exercise testing. Additionally, the exercise protocol employed in the present 16 study elicited similar cardiorespiratory responses between trials and a strong relationship was 17 identified between cardiac output and peak oxygen consumption for both trials. This 18 illustrates the ability of the exercise protocol to elicit reliable hemodynamic and 19 cardiorespiratory responses on separate occasions in the absence of changes in health and 20 clinical status of an individual. 21
22
The assessment of cardiac output in a reliable manner is an essential tool to accurately assess 23 any improvements or decrements in cardiac function of numerous patient groups. As 24 previously stated this is of particular importance in cardiac patients as small changes in 25 cardiopulmonary data due to disease or intervention may have significant clinical 1 implications 30 . It may therefore be suggested that inaccurate and unreliable measures may 2 contribute to misinterpretation of data and potentially misdiagnosis. The excellent reliability 3 of bioreactance in measuring haemodynamics (at rest and continuously during exercise) 4 reported in the present study illustrates its potential clinical application. Furthermore, its 5 ability to assess cardiac output noninvasively, inexpensively and without specialist training of 6 the assessor permits its application in an increased number of patient groups when compared 7 to more invasive and "gold standard" catheter based measurement techniques 11 12 . 8 9
The CO values reported in the present study are consistent with recent research employing 10 bioreactance in a comparable population and at similar exercise intensities 19 . The authors 11 Jakovljevic, et al. 19 reported resting CO values of 6.5 L min -1 which are similar to those 12 reported in the present study. Similar values were also reported at comparable submaximal 13 and near maximal exercise intensities. Furthermore the CO data previously reported 19 was 14 consistently correlated with CO estimates derived from measured oxygen consumption 31 . We 15 have also demonstrated a strong relationship between cardiac output and oxygen 16 consumption at peak exercise in the present study. Elliott, et al. 25 also reported similar CO as 17 assessed via bioreactance at similar exercise intensities as the present study and previous 18 study 19 . In addition resting and near maximal cardiac index reported in the present study is 19 similar to that previously reported 25 . The data presented in this article further substantiates 20 the previous work 19 25 and demonstrates that bioreactance is accurate and reliable for 21 assessing haemodynamic variables at various exercise intensities. Furthermore, cardiac 22 output data from the present study that are associated particularly with stages of low to 23 moderate intensities are consistent with those identified in different stages of heart failure 26 27 . 24 Overall, data presented in the present study indicate that bioreactance can provide reliable measures of cardiac output independent of any other physiological measures (e.g. oxygen 1 consumption) and potential elevated electrical noise, body motion, perspiration and body 2 temperature associated with graded exercise. 3 4 The present study is not without limitations. Firstly, the study participants were young, 5 healthy adults whereas older people and those with chronic conditions were not included. It 6 may be speculated therefore that the present findings cannot be generalized to a wider, 7 clinical applications. However, the study protocol allowed analysis of bioreactance cardiac 8 output test-retest reliability not only at peak exercise but also at low to moderate levels of 9 exercise intensities that are often observed in individuals with chronic conditions and in older 10 people. Secondly, no gold standard for cardiac output measurement (i.e. thermodilution or 11 direct Fick) was included. The additional risks posed to the study participants with these 12 procedures precluded them from being undertaken. 13 14
Conclusions
15
In conclusion, bioreactance method demonstrates good test-retest reliability for estimating 16 cardiac output and stroke volume at rest and during different stages of graded exercise testing 17 including maximal exertion. Future large studies are warranted to assess the reliability of 18 bioreactance at both rest and exercise in different clinical groups where monitoring of cardiac 19 output has been shown to improve risk stratification and clinical outcomes. Comparison of cardiac output determined by different rebreathing methods at rest and at peak 29 1.6 (0.9) 1.6 (0.9) 0.882 Note: p value determined from test-retest data using paired sample t-test for measurement 5 outcomes. Data analyses performed on resting and exercise data combined (n = 22, data 6 points =132). 7 Note: Sx = standard error of the mean, SD = standard deviation, SRD = smallest real 4 difference. Data analyses performed on resting and exercise data combined (n = 22, data 5 points =132). 6 7 
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